Investors & Media

Whats new.

Press releases

Press releases.

Immutep Quarterly Activities Report & Appendix 4C

April 19th 2021
press releases

Immutep Receives A$1,155,055 R&D Tax Incentive

April 16th 2021
press releases

Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer

April 8th 2021
press releases

Investor updates

Investor updates.

Investor Update - April 2021

April 14th 2021
investor updates

Investor Update - August 2020

August 17th 2020
investor updates

Investor Update - November 2019

November 22nd 2019
investor updates

Analyst reports

Analyst reports.

Bell Potter - Efti granted Fast Track - A vote of confidence (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor.

April 9th 2021
analyst reports

Alliance Global Partners - FDA's Fast Track for Efti Suggests Regulators Echo Large Pharma Enthusiasm Surrounding LAG-3 Immunotherapy

April 8th 2021
analyst reports

Bell Potter - Validation for LAG-3 arrives (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor.

March 31st 2021
analyst reports